RxDoctor Payments Data

Arminda Lumapas, MD

Rheumatology · Concord Twp, OHNPI 1750587754

Payments from drug & device makers

$9,623in general payments, 2019–2025

Across 598 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • UCB, Inc.$1K
  • Novartis$840
  • Pfizer$812
  • Johnson & Johnson$778
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,34297%
  • Education$2813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,623 in reported general payments places this provider in the 70th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$90,869
Medicare patients
486
Services billed
1,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab101$747,273
RinvoqUpadacitinib98$653,541
Xeljanz XrTofacitinib Citrate102$615,709
Orencia ClickjectAbatacept92$515,670
Enbrel SureclickEtanercept60$436,817
Cosentyx Sensoready PenSecukinumab26$326,339
EnbrelEtanercept44$325,472
ProliaDenosumab104$175,910
Cosentyx Sensoready (2 Pens)Secukinumab23$169,044
Taltz AutoinjectorIxekizumab20$135,288
Cimzia (2 Pack)Certolizumab Pegol21$133,094
BenlystaBelimumab28$132,879
KevzaraSarilumab19$128,142
ActemraTocilizumab37$122,719
Teriparatide25$59,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,413$653,54198 claims
AmgenEnbrel, Prolia$1,396$501,383148 claims
UCB, Inc.Cimzia (2 Pack)$1,215$133,09421 claims
GSKBenlysta$385$132,87928 claims
SanofiKevzara$38$128,14219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Concord Twp

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →